Corbus Pharmaceuticals Holdings (CRBP) EBIT Margin (2015 - 2021)
Corbus Pharmaceuticals Holdings' (CRBP) quarterly EBIT Margin came in at 14257.07% in Q3 2021, down 1149635.0% year-on-year from N/an in Q3 2020, and down 16.57% quarter-over-quarter from 12230.01% in Q2 2021.
Corbus Pharmaceuticals Holdings (CRBP) EBIT Margin (2015 - 2021) Analysis & Trends
Corbus Pharmaceuticals Holdings' EBIT Margin history runs 7 years deep, the most recent figure standing at 14257.07% for Q3 2021.
- On a quarterly basis, EBIT Margin fell 1149635.0% year-over-year to 14257.07% in Q3 2021; TTM through Jun 2022 was 45961.32%, a 4363525.0% decrease from a year earlier, with the FY2021 full-year figure at 6350.09%, down 389388.0% from the prior year.
- EBIT Margin retreated to 14257.07% in Q3 2021 per CRBP's latest filing, from 12230.01% in the prior quarter.
- Across five years, EBIT Margin topped out at 95.17% in Q4 2019 and bottomed at 14257.07% in Q3 2021.
- The 5-year median for EBIT Margin is 1429.2% (2018), against an average of 3693.1%.
- Across the five-year window, EBIT Margin jumped 884691 bps in 2019 and slumped 1332495 bps in 2020, its largest moves.
- Year by year, EBIT Margin stood at 873.63% in 2017, then plunged by 902 bps to 8751.74% in 2018, then jumped by 101 bps to 95.17% in 2019, then tumbled by 1371 bps to 1209.33% in 2020, then tumbled by 1079 bps to 14257.07% in 2021.
- Per Business Quant, the three latest CRBP EBIT Margin figures stand at 14257.07% (Q3 2021), 12230.01% (Q2 2021), and 2379.38% (Q1 2021).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 164.14 Mn | 136.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -14,257.07% |
| Jun 30, 2021 | -12,230.01% |
| Mar 31, 2021 | -2,379.38% |
| Dec 31, 2020 | -1,209.33% |
| Sep 30, 2020 | -2,760.72% |
| Jun 30, 2020 | -13,319.09% |
| Mar 31, 2020 | -1,696.04% |
| Dec 31, 2019 | 95.17% |
| Sep 30, 2019 | -969.07% |
| Jun 30, 2019 | 5.86% |
| Mar 31, 2019 | -1,406.53% |
| Dec 31, 2018 | -8,751.74% |
| Sep 30, 2018 | -1,365.69% |
| Jun 30, 2018 | -1,451.86% |
| Mar 31, 2018 | -1,248.36% |
| Sep 30, 2017 | -873.63% |
| Jun 30, 2017 | -2,082.20% |
| Mar 31, 2017 | -576.07% |
| Sep 30, 2016 | -718.30% |
| Jun 30, 2016 | -1,056.90% |